Drugs / 67Cu-SARTATE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04023331 | Aug 2020 → Jan 2025 | neuroblastoma | Clarity Pharmaceuticals Ltd | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03936426 | Jul 2018 → Sep 2019 | meningioma | Clarity Pharmaceuticals Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 67Cu-SARTATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04023331 ↗ |
| Known as | Cu-67 SARTATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03936426 ↗ |
| Modality | Peptide | “attached to the somatostatin analog octreotate using the sarcophagine MeCOSar chelator (SARTATE)” PMID 36460344 ↗ Dec 2022 |
| Route | Intravenous | “Cu-67 SARTATE via a slow intravenous infusion over 30 minutes” NCT03936426 ↗ |